Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Key Highlights
- ➤Organon plans to report third-quarter 2026 results through its Form 10-Q filing.
- ➤Organon expects no milestone expense in the third quarter of 2026.
- ➤Organon suspended quarterly earnings calls during Sun Pharma’s proposed acquisition.
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the third quarter 2026, which will be disclosed in a Form 8-K filing to be filed on the same day as the Form 10-Q. During the pendency of the previously announced acquisition by Sun Pharmaceutical Industries Limited on April 26, 2026, Organon has suspended its quarterly earnings calls.
Get started
Create a free account to read the full story.